Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years save search
Progressive Care, Inc. Announces Reverse Stock Split and Will Trade Under Temporary Symbol RXMDD
Published: 2022-12-30 (Crawled : 15:00) - globenewswire.com
RXMD | $1.93 4.32% 174.55% 8.3K
|
Retail Trade
|
| O: 916.95%
H: 2230.0%
C: 2066.67%
PARTY CITY SHAREHOLDER NOTICE: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Party City To Contact Him Directly To Discuss Their Options
Published: 2023-09-27 (Crawled : 22:00) - prnewswire.com
PRTYQ | $0.004 200.0% 28K
|
n/a
|
| O: -86.96%
H: 1566.67%
C: 833.33%
city
Week in Review: August 11, 2023
Published: 2023-08-14 (Crawled : 15:20) - myfw.com
FRCB | $0.04 18.59% 59K
|
n/a
|
| O: -87.1%
H: 712.5%
C: 700.0%
week
MicroCloud Hologram Planned to Join the Communications Industry Association
Published: 2024-02-07 (Crawled : 11:00) - prnewswire.com
HOLO | $2.95 31.7% 22.49% 37M
|
|
| O: 149.01%
H: 395.74%
C: 378.72%
association communications
Dais Shares Summary of Its Progress in 2022 With a Glimpse Into 2023
Published: 2023-01-17 (Crawled : 18:00) - globenewswire.com
DLYT | $0.0073 -58.76% -17.6% 0
|
|
| O: -79.0%
H: 366.67%
C: 366.67%
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
Published: 2023-10-10 (Crawled : 20:00) - globenewswire.com
TPST | $3.17 -3.06% -2.83% 310K
|
Manufacturing
|
| O: 787.87%
H: 358.69%
C: 358.69%
tpst-1120 report global study
Tempest Adopts Limited Duration Stockholder Rights Plan
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
TPST | $3.17 -3.06% -2.83% 310K
|
Manufacturing
|
| O: 787.87%
H: 358.69%
C: 358.69%
Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
TPST | $3.17 -3.06% -2.83% 310K
|
Manufacturing
|
| O: 787.87%
H: 358.69%
C: 358.69%
tpst-1120 arm study
Cell MedX Corp. Announces New CEO and Directors and Debt Settlement
Published: 2023-12-19 (Crawled : 21:00) - biospace.com/
CMXC | $0.048 60.0% -63.33% 0
|
Manufacturing
|
| O: 0.0%
H: 415.38%
C: 330.77%
ceo cell
Trevena Announces Approval of OLINVYK in China
Published: 2023-05-08 (Crawled : 11:00) - globenewswire.com
TRVN | $0.366 -8.96% -10.05% 8.3K
|
Health Technology
|
| O: 23.32%
H: 322.19%
C: 300.31%
approval olinvyk china
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Published: 2022-03-28 (Crawled : 17:00) - biospace.com/
THER | $0.001 62.5% 0
|
n/a
|
| O: -80.0%
H: 400.0%
C: 300.0%
theralink health care collaboration cancer
Endo, Inc. Announces Proposed Private Offering of Senior Secured Notes
Published: 2024-04-08 (Crawled : 12:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -90.0%
H: 300.0%
C: 300.0%
offering
Endo, Inc. Announces Proposed New Senior Secured Credit Facilities
Published: 2024-04-01 (Crawled : 16:00) - prnewswire.com
ENDPQ | $0.0006 -50.0% 3.4K
|
n/a
|
| O: -75.0%
H: 1900.0%
C: 300.0%
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
Published: 2022-12-09 (Crawled : 14:00) - biospace.com/
AMAM 4 | $28.0 0.0% 1.4M
|
Professional, Scientific, and T...
|
| O: 185.44%
H: 288.03%
C: 288.03%
arx788 treatment breast positive cancer her2- her2 metastatic breast cancer
Rocky Mountain High Brands, Inc. Recaps Company’s OTC Quarterly Filings For 2023
Published: 2024-02-28 (Crawled : 14:00) - globenewswire.com
RMHB | $0.0101 1.0% 36.36% 0
|
|
| O: -66.67%
H: 275.0%
C: 275.0%
Clubhouse Media Group, Inc. Closes Promo Deal With Rob Gronkowski, Four-Time Super Bowl Champion
Published: 2022-06-22 (Crawled : 13:00) - prnewswire.com
CMGR | $0.0003 -50.0% 250
|
Health Care and Social Assistan...
|
| O: 12.0%
H: 671.43%
C: 246.43%
media deal
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
Published: 2023-11-29 (Crawled : 12:30) - globenewswire.com
VVOS | $2.66 -2.66% 63K
|
Health Technology
|
| O: 171.75%
H: 308.97%
C: 243.67%
fda device treatment clearance therapeutics
SolarWindow Appoints New Directors and Auditor to Korean Subsidiary
Published: 2023-05-23 (Crawled : 15:00) - globenewswire.com
WNDW | $0.31 -6.06% 61.29% 0
|
Manufacturing
|
| O: -79.17%
H: 240.0%
C: 240.0%
Mitesco Provides Shareholder Update
Published: 2024-02-15 (Crawled : 14:00) - globenewswire.com
MITI | $0.26 -36.43% -9.99% 0
|
Manufacturing
|
| O: -69.23%
H: 524.5%
C: 225.0%
update
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.46 0.37% 0.91% 5.7K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
ZCMD | $1.45 5.84% 49.63% 15M
|
Commercial Services
AULT | $0.2421 -7.7% 45.23% 16M
|
Manufacturing
XPON | News | $3.15 63.21% 33.9% 100K
|
EGOX | $0.036 12.15% 31.56% 32M
|
TIRX | $0.8 65.02% 25.95% 410K
|
VTNR 4 | $1.31 33.78% 25.82% 220K
|
Industrial Services
GDHG | $0.263 21.76% 25.34% 1.3M
|
TPET | $0.3279 -3.56% 23.57% 11M
|
n/a
HOLO | $2.95 31.7% 22.49% 37M
|
MTNB | $0.19 -1.04% 14.58% 950K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.